Company intelligence / Profile preview

Cardiotech

Wilmington/Woburn, Massachusetts, United Statescardiotech.org ↗

Ownership: Private
Development stage: Commercial

Overview

Historically, CardioTech conducted clinical trials in Europe for its synthetic coronary bypass graft ("CardioPass") but no recent results are available. The company’s focus shifted to biomaterials supply via AdvanSource Biomaterials after restructuring in 2008. Regional distributors like CardioTech SARL distribute approved cardiac devices but do not develop novel therapeutics themselves.

Therapeutic areas: Cardiovascular
Modalities: DeviceBiologic materials/biomaterials
Industry: Chemicals & Materials

Drug pipeline

1 asset

CardioPass

Clinical Trial

Indications: Coronary artery disease

Partnerships

No major pharma/biotech partnerships reported recently.

Beyond the preview

Go deeper on Cardiotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiotech.

Explore the full profile